Journal: Frontiers in Cellular and Infection Microbiology
Article Title: A novel approach to designing viral precision vaccines applied to SARS-CoV-2
doi: 10.3389/fcimb.2024.1346349
Figure Lengend Snippet: IgG and T-cell response of patients with COVID-19 to SARS-CoV-2 S protein junction-derived antigens: (A) Results of the ELISA experiment with protein subunits SJ/FT and P3-L and the sera from 500 COVID-19 patients. (B) IFN-γ production analysis: PBMCs from COVID-19 patients with mild disease (MD, green), COVID-19 patients with severe disease (SD, red) or healthy controls (HC, blue) were stimulated with S protein junction-derived proteins P3-L or SJ/FT and polypeptides P3/FUR/x3 or P4/TMP/x3 at a final concentration of 10 µg/ml. At 10 days, cells were collected and ELISpot was used to measure IFN-γ production by. Histograms represent the median with interquartile range. Statistical analysis: * indicates a significant difference at p <0.05 and ** p<0.001.
Article Snippet: To test the cohort of patients with COVID-19 for IgG to the SARS-CoV-2 S protein RBD region, we used a commercial quantitative ELISA kit (RayBio COVID-19 S1 RBD protein Human IgG ELISA kit; RayBiotech; Parkway, USA).
Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Enzyme-linked Immunospot